What is the primary purpose of the Collaboration and Expansion Agreements?

The primary purpose is to expand the global development and commercialization of Amgen's proprietary product, denosumab. The agreements leverage GSK's international presence and expertise to bring denosumab to a wider patient population for osteoporosis and potentially other indications.

What financial terms are included in these agreements?

GSK will provide Amgen with an initial payment and near-term commercial milestone payments totaling $120 million. In the Primary Territories, Amgen and GSK will share profits and expenses equally, with Amgen also receiving a tiered royalty (Inventorship Margin). In the Expansion Territories, Amgen will sell denosumab to GSK at agreed-upon amounts.

What are Amgen's retained rights under these agreements?

Amgen retains all commercialization rights for denosumab for osteoporosis in the United States and Canada. Amgen also retains all commercialization rights for oncology indications in the United States, Canada, and the Primary Territories (Europe, Australia, New Zealand, and Mexico). Amgen also has options for expanded commercialization roles in both Primary and Expansion Territories in the future.

How will revenue and expenses be managed in the partnered territories?

In the Primary Territories (Europe, Australia, New Zealand, Mexico), Amgen and GSK will share profits and future expenses equally after accounting for Amgen's Inventorship Margin. In the Expansion Territories (e.g., China, Brazil, India), GSK will bear all development and commercialization costs and will purchase denosumab from Amgen to meet demand.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) has announced a significant strategic partnership with Glaxo Group Limited, a subsidiary of GlaxoSmithKline plc (GSK), through two agreements: a Collaboration Agreement and an Expansion Agreement. These agreements focus on the development and commercialization of Amgen's proprietary product, denosumab, a treatment for osteoporosis and potentially other indications. This collaboration grants GSK significant rights in various international territories, aiming to expand denosumab's global reach and leverage GSK's established commercial infrastructure. Under the Collaboration Agreement, Amgen and GSK will co-commercialize denosumab for osteoporosis in Europe, Australia, New Zealand, and Mexico, with Amgen retaining US and Canadian rights for this indication. Amgen also retains US and Canadian rights for oncology indications, along with co-commercialization rights in the primary territories. GSK will make initial payments and milestone payments totaling $120 million to Amgen, and profits and future expenses will be shared equally, with Amgen receiving a tiered royalty reflecting its innovation. The Expansion Agreement further extends GSK's role to commercialize denosumab for all indications in additional territories such as China, Brazil, and India, with GSK bearing all costs and purchasing denosumab from Amgen.

Key Highlights

1Amgen enters into a material definitive agreement with Glaxo Group Limited (GSK) for denosumab.
2The agreement involves a Collaboration Agreement and an Expansion Agreement for denosumab's development and commercialization.
3GSK will co-commercialize denosumab for osteoporosis in Europe, Australia, New Zealand, and Mexico, with Amgen retaining US/Canada rights for this indication.
4Amgen retains US/Canada rights for denosumab in oncology indications.
5GSK will pay Amgen an initial payment and near-term commercial milestones totaling $120 million.
6Profits and future commercialization expenses for the partnered territories will be shared equally between Amgen and GSK, with Amgen receiving an 'Inventorship Margin' royalty.
7GSK will commercialize denosumab for all indications in additional territories (Expansion Territories) and bear all associated costs, purchasing denosumab from Amgen.

AMGEN INC 8-K Report, Material Agreement (Jul 27, 2009)

Summary

Key Highlights

Frequently Asked Questions